With Biogen’s decision to exit the US biosimilar market, Samsung Bioepis had to find a new marketing partner for its biosimilar ophthalmology portfolio. On July 17th, the company announced that its search for a replacement was over: It had entered a new license, development, and commercialization agreement with Harrow. Harrow will assume marketing responsibilities for … Continue reading Samsung Bioepis Finds New Commercial Partner for Its Ophthalmology Biosimilars